Effect of hyperinsulinemia during hemodialysis on the insulin-like growth factor system and inflammatory biomarkers: A randomized open-label crossover study

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Reinhard, Mark ^a   Frystyk, Jan ^a,b   Jespersen, Bente ^a   Bjerre, Mette ^a,b   Christiansen, Jens S ^a,b   Flyvbjerg, Allan ^a,b   Ivarsen, Per ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Bioactive IGF I; Hemodialysis; IGFBP 1; Inflammation; Insulin; Nutrition

Indexed keywords

ALBUMIN; BICARBONATE; C REACTIVE PROTEIN; GLUCOSE; INSULIN; INSULIN ASPART; INTERLEUKIN 1BETA; INTERLEUKIN 6; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GRANULOMATOSIS; HEMODIALYSIS; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN INFUSION; INSULIN RELEASE; KIDNEY POLYCYSTIC DISEASE; MALE; MEDULLARY SPONGE KIDNEY; OPEN STUDY; OUTCOME ASSESSMENT; PH; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; VASCULITIS; BLOOD; CHEMICALLY INDUCED; HYPERINSULINISM; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY; TRENDS;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CROSS-OVER STUDIES; FEMALE; GLUCOSE; HUMANS; HYPERINSULINISM; INFLAMMATION MEDIATORS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 84875688508     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-80     Document Type: Article

References (53)

1. Multimodal approach to malnutrition in malnourished maintenance hemodialysis patients. Cano NJ, Heng AE, Pison C, J Ren Nutr 2011 21 23 26 10.1053/j.jrn.2010.10.016 21195913
2. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Kidney Int 2008 73 391 398 10.1038/sj.ki.5002585 18094682
3. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Frystyk J, Ivarsen P, Skjaerbaek C, Flyvbjerg A, Pedersen EB, Orskov H, Kidney Int 1999 56 2076 2084 10.1046/j.1523-1755.1999.00798.x 10594783
4. Growth hormone, IGF-I and its binding proteins (IGFBP-1 and -3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis. Iglesias P, Diez JJ, Fernandez-Reyes MJ, Mendez J, Bajo MA, Aguilera A, Selgas R, Clin Endocrinol (Oxf) 2004 60 741 749 10.1111/j.1365-2265.2004.02049.x
5. Insulin is protein-anabolic in chronic renal failure patients. Lim VS, Yarasheski KE, Crowley JR, Fangman J, Flanigan M, J Am Soc Nephrol 2003 14 2297 2304 10.1097/01.ASN.0000085590.83005.A0 12937306
6. Effect of a single hemodialysis session on inflammatory markers. Bitla AR, Reddy PE, Manohar SM, Vishnubhotla SV, Pemmaraju Venkata Lakshmi Narasimha SR, Hemodial Int 2010 14 411 417 10.1111/j.1542-4758.2010.00491.x 20955274
7. Cytokine patterns and survival in haemodialysis patients. Cohen SD, Phillips TM, Khetpal P, Kimmel PL, Nephrol Dial Transplant 2010 25 1239 1243 10.1093/ndt/gfp625 20007982
8. Protein damage and inflammation in uraemia and dialysis patients. Galli F, Nephrol Dial Transplant 2007 22 Suppl 5 v36 17586842
9. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimburger O, Cederholm T, Girndt M, Kidney Int 2005 67 1216 1233 10.1111/j.1523-1755.2005.00200.x 15780075
10. Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Ikizler TA, Pupim LB, Brouillette JR, Levenhagen DK, Farmer K, Hakim RM, Flakoll PJ, Am J Physiol Endocrinol Metab 2002 282 107 E116 11739090
11. The effect of hemodialysis on protein metabolism. A leucine kinetic study. Lim VS, Bier DM, Flanigan MJ, Sum-Ping ST, J Clin Invest 1993 91 2429 2436 10.1172/JCI116477 8514855
12. Protein turnover and amino acid transport kinetics in end-stage renal disease. Raj DS, Zager P, Shah VO, Dominic EA, Adeniyi O, Blandon P, Wolfe R, Ferrando A, Am J Physiol Endocrinol Metab 2004 286 136 E143 13129859
13. Does hemodialysis increase protein breakdown? Dissociation between whole-body amino acid turnover and regional muscle kinetics. Lim VS, Ikizler TA, Raj DS, Flanigan MJ, J Am Soc Nephrol 2005 16 862 868 10.1681/ASN.2004080624 15716333
14. Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients. Bossola M, Sanguinetti M, Scribano D, Zuppi C, Giungi S, Luciani G, Torelli R, Posteraro B, Fadda G, Tazza L, Clin J Am Soc Nephrol 2009 4 379 385 10.2215/CJN.03490708 19118119
15. Interleukin-6 modulates hepatic and muscle protein synthesis during hemodialysis. Raj DS, Moseley P, Dominic EA, Onime A, Tzamaloukas AH, Boyd A, Shah VO, Glew R, Wolfe R, Ferrando A, Kidney Int 2008 73 1054 1061 10.1038/ki.2008.21 18288103
16. Inflammatory signals associated with hemodialysis. Caglar K, Peng Y, Pupim LB, Flakoll PJ, Levenhagen D, Hakim RM, Ikizler TA, Kidney Int 2002 62 1408 1416 10.1111/j.1523-1755.2002.kid556.x 12234313
17. The effects of infusion of insulinlike growth factor (IGF) I, IGF-II, and insulin on glucose and protein metabolism in fasted lambs. Douglas RG, Gluckman PD, Ball K, Breier B, Shaw JH, J Clin Invest 1991 88 614 622 10.1172/JCI115346 1864971
18. Acute in vivo elevation of insulin-like growth factor (IGF) binding protein-1 decreases plasma free IGF-I and muscle protein synthesis. Lang CH, Vary TC, Frost RA, Endocrinology 2003 144 3922 3933 10.1210/en.2002-0192 12933666
19. Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism. Fryburg DA, Am J Physiol 1994 267 331 E336 8074213
20. Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. Fryburg DA, Jahn LA, Hill SA, Oliveras DM, Barrett EJ, J Clin Invest 1995 96 1722 1729 10.1172/JCI118217 7560063
21. Free insulin-like growth factors-measurements and relationships to growth hormone secretion and glucose homeostasis. Frystyk J, Growth Horm IGF Res 2004 14 337 375 10.1016/j.ghir.2004.06.001 15336229
22. Bioactive rather than total IGF-I is involved in acute responses to nutritional interventions in CAPD patients. Brugts MP, Tjiong HL, Rietveld T, Wattimena JL, van den Berg JW, Fieren MW, Janssen JA, Nephrol Dial Transplant 2010 25 940 946 10.1093/ndt/gfp576 19903658
23. Marked reductions in bioactive insulin-like growth factor I (IGF-I) during hemodialysis. Ivarsen P, Chen JW, Tietze I, Christiansen JS, Flyvbjerg A, Frystyk J, Growth Horm IGF Res 2010 20 156 161 10.1016/j.ghir.2009.12.001 20044291
24. Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients. Pupim LB, Flakoll PJ, Brouillette JR, Levenhagen DK, Hakim RM, Ikizler TA, J Clin Invest 2002 110 483 492 12189242
25. Tissue-specific regulation of IGF-I and IGF-binding proteins in response to TNFalpha. Lang CH, Nystrom GJ, Frost RA, Growth Horm IGF Res 2001 11 250 260 10.1054/ghir.2001.0233 11735242
26. Uremia attenuates growth hormone-stimulated insulin-like growth factor-1 expression, a process worsened by inflammation. Chen Y, Biada J, Sood S, Rabkin R, Kidney Int 2010 78 89 95 10.1038/ki.2010.85 20375991
27. IL-1 receptor antagonist attenuates sepsis-induced alterations in the IGF system and protein synthesis. Lang CH, Fan J, Cooney R, Vary TC, Am J Physiol 1996 270 430 E437 8638689
28. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. Zhang L, Rajan V, Lin E, Hu Z, Han HQ, Zhou X, Song Y, Min H, Wang X, Du J, FASEB J 2011 25 1653 1663 10.1096/fj.10-176917 21282204
29. The regulation of insulin-like growth factor binding protein (IGFBP)-1 during prolonged fasting. Cotterill AM, Holly JM, Wass JA, Clin Endocrinol (Oxf) 1993 39 357 362 10.1111/j.1365-2265.1993.tb02377.x
30. Regulation and function of insulin-like growth factor-binding protein-1. Lee PD, Conover CA, Powell DR, Proc Soc Exp Biol Med 1993 204 4 29 7690486
31. Insulin as an anti-inflammatory and antiatherogenic modulator. Dandona P, Chaudhuri A, Ghanim H, Mohanty P, J Am Coll Cardiol 2009 53 14 S20 10.1016/j.jacc.2008.10.038 19179212
32. Anti-inflammatory effect of an insulin infusion in patients on maintenance haemodialysis: A randomized controlled pilot study. Vos FE, Manning PJ, Sutherland WH, Schollum JB, Walker RJ, Nephrology (Carlton) 2011 16 68 75 10.1111/j.1440-1797.2010.01329.x
33. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Davies SJ, Phillips L, Naish PF, Russell GI, Nephrol Dial Transplant 2002 17 1085 1092 10.1093/ndt/17.6.1085 12032201
34. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Frystyk J, Dinesen B, Orskov H, Growth Regul 1995 5 169 176 8745141
35. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Chen JW, Ledet T, Orskov H, Jessen N, Lund S, Whittaker J, De MP, Larsen MB, Christiansen JS, Frystyk J, Am J Physiol Endocrinol Metab 2003 284 1149 E1155 12604504
36. Quantification of the GH/IGF-axis components: Lessons from human studies. Frystyk J, Domest Anim Endocrinol 2012 43 186 197 10.1016/j.domaniend.2011.11. 005 22153974
37. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. Krassas GE, Pontikides N, Kaltsas T, Dumas A, Frystyk J, Chen JW, Flyvbjerg A, J Clin Endocrinol Metab 2003 88 132 135 10.1210/jc.2002-021349 12519841
38. The phosphorylation pattern of insulin-like growth factor-binding protein-1 in normal plasma is different from that in amniotic fluid and changes during pregnancy. Westwood M, Gibson JM, Davies AJ, Young RJ, White A, J Clin Endocrinol Metab 1994 79 1735 1741 10.1210/jc.79.6.1735 7527409
39. Haemodialysis with the biocompatible high permeability AN-69 membrane does not alter plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3. Bohe J, Joly MO, Arkouche W, Laville M, Fouque D, Nephrol Dial Transplant 2001 16 590 594 10.1093/ndt/16.3.590 11239037
40. What is subjective global assessment of nutritional status? Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Mendelson RA, Jeejeebhoy KN, JPEN J Parenter Enteral Nutr 1987 11 8 13 10.1177/014860718701100108 3820522
41. Intradialytic oral nutrition improves protein homeostasis in chronic hemodialysis patients with deranged nutritional status. Pupim LB, Majchrzak KM, Flakoll PJ, Ikizler TA, J Am Soc Nephrol 2006 17 3149 3157 10.1681/ASN. 2006040413 17021267
42. Protein intake during hemodialysis maintains a positive whole body protein balance in chronic hemodialysis patients. Veeneman JM, Kingma HA, Boer TS, Stellaard F, De Jong PE, Reijngoud DJ, Huisman RM, Am J Physiol Endocrinol Metab 2003 284 954 E965 12540372
43. Insulin-like growth factor-binding protein-1 response to insulin during suppression of endogenous insulin secretion. Lee PD, Jensen MD, Divertie GD, Heiling VJ, Katz HH, Conover CA, Metabolism 1993 42 409 414 10.1016/0026- 0495(93)90095-6 7683739
44. Lack of growth hormone effect on insulin-associated suppression of insulinlike growth factor binding protein 1 in humans. Conover CA, Butler PC, Wang M, Rizza RA, Lee PD, Diabetes 1990 39 1251 1256 10.2337/diabetes.39.10.1251 1698676
45. The effect of oral glucose on serum free insulin-like growth factor-I and -II in health adults. Frystyk J, Grofte T, Skjaerbaek C, Orskov H, J Clin Endocrinol Metab 1997 82 3124 3127 10.1210/jc.82.9.3124 9284756
46. Suppression of endogenous insulin secretion regulates the rapid rise of insulin-like growth factor binding protein (IGFBP)-1 levels following acute hypoglycaemia. Cotterill AM, Holly JM, Amiel S, Wass JA, Clin Endocrinol (Oxf) 1993 38 633 639 10.1111/j.1365-2265.1993.tb02146.x
47. Clinical evaluation of plasma insulin and C-peptide levels with 3 different high-flux dialyzers in diabetic patients on hemodialysis. Abe M, Okada K, Maruyama T, Inoshita A, Ikeda K, Uto E, Kikuchi F, Matsumoto K, Int J Artif Organs 2008 31 898 904 19009508
48. Removal of hormones by hemofiltration and hemodialysis with a highly permeable polysulfone membrane. Wizemann V, Velcovsky HG, Bleyl H, Bruning S, Schutterle G, Contrib Nephrol 1985 46 61 68 2408819
49. Diets and enteral supplements for improving outcomes in chronic kidney disease. Kalantar-Zadeh K, Cano NJ, Budde K, Chazot C, Kovesdy CP, Mak RH, Mehrotra R, Raj DS, Sehgal AR, Stenvinkel P, Nat Rev Nephrol 2011 7 369 384 21629229
50. Nutritional supplementation acutely increases albumin fractional synthetic rate in chronic hemodialysis patients. Pupim LB, Flakoll PJ, Ikizler TA, J Am Soc Nephrol 2004 15 1920 1926 10.1097/01.ASN.0000128969.86268.C0 15213282
51. Coordinated increase in albumin, fibrinogen, and muscle protein synthesis during hemodialysis: role of cytokines. Raj DS, Dominic EA, Wolfe R, Shah VO, Bankhurst A, Zager PG, Ferrando A, Am J Physiol Endocrinol Metab 2004 286 658 E664 10.1152/ajpendo.00444.2003 14722024
52. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. Korevaar JC, van Manen JG, Dekker FW, de Waart DR, Boeschoten EW, Krediet RT, J Am Soc Nephrol 2004 15 2916 2922 10.1097/01.ASN.0000143744.72664.66 15504945
53. Changes in circulating biomarkers during a single hemodialysis session. Yamamoto T, Nascimento MM, Hayashi SY, Qureshi AR, Waniewski J, Brodin LA, Anderstam B, Lind B, Riella MC, Seeberger A, Hemodial Int 2013 17 59 66 10.1111/j.1542-4758.2012.00720.x 22716238